Article

LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein Aggregates

2024-07-22

Abstract excerpt

<h4>Background</h4> Among LRRK2-associated parkinsonism cases with nigral degeneration, over two-thirds demonstrate evidence of pathologic alpha-synuclein, but many do not. Understanding the clinical phenotype and underlying biology in such individuals is critical for therapeutic development. Our objective was to compare clinical and biomarker features, and rate of progression over 4 years follow-up, among LRRK2-a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ce50c16d-f3e3-59de-8e13-6c50f7973345
DOI: 10.1101/2024.07.22.24310806

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein AggregatesDOI 10.1101/2024.07.22.24310806Read

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationSemantic proximity Read

Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson’s disease in the PPMI cohortSemantic proximity Read

Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional studySemantic proximity Read

Diagnostic and prognostic value of alpha-synuclein seed amplification assay in Parkinson’s disease: a longitudinal cohort studySemantic proximity Read

Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataSemantic proximity Read

Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disordersSemantic proximity Read

Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson’s Disease at 10-year follow-upSemantic proximity Read

Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-Synuclein Seeding ActivitySemantic proximity Read

The α-Synuclein seeding assay discriminates between LRRK2 p.Gly2019Ser variant carriers with and without Parkinson’s diseaseSemantic proximity Read

SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s diseaseSemantic proximity Read

<i>RAB32</i>-linked Parkinson’s disease: Deep phenotyping, MDSGene literature review, and application of SynNeurGe criteriaSemantic proximity Read

Pathology and genetics in a global cohort of Parkinsonian DisordersSemantic proximity Read